The high price of new hepatitis C drugs is keeping them out of reach of many prison inmates limiting the ability to cure the disease in one of the nations largest infected populations  Two treatments introduced late last year have steep price tags Gilead Sciences Incs Sovaldi has a list price of  per patient for a standard week treatment while Johnson  Johnsons Olysio costs  for the same duration  
  